Stryker Biotech agrees to a $15 million settlement with federal prosecutors on charges that it ran an off-label promotion scheme, pleading guilty to a single misdemeanor count of distributing a mis-branded device.

Stryker Biotech agreed to cough up $15 million and and pleaded guilty to a single misdemeanor today, ending federal charges that it ran an illegal off-label promotion scheme.
The millions of dollars in fees that medical device companies pay for FDA review aren't exempt from...
EnteroMedics expects to file for pre-market approval from the FDA this quarter for its Maestro vagal...
Natus Medical beats Wall Street's earnings forecast with a 1,000-fold profit surge on record sales,...
The U.S. Supreme Court agrees to hear Medtronic's appeal of a patent infringement loss to rival...
The New York Times lists the 10 most expensive hospitals in the United States, based on CMS data